Athersys (ATHX), Results from early Heart Attack clinical trial
June 15th, 2011
No comments
ATHX reported that results from a P1 trial of its stem cell therapy Read more…
Archive
Archive for the ‘NASDAQ: ATHX’ Category
Earnings: Athersys (ATHX) Q1/11 Results
May 6th, 2011
No comments
Q1/11 net loss was $3.93M or $0.18 per share Read more…
Categories: NASDAQ: ATHX, Q1/11 Results, Stem Cell Research
Athersys (ATHX) Q4/10 Results
March 15th, 2011
No comments
Net loss of $2.05M or $0.11 per share Read more…
Categories: NASDAQ: ATHX, Q4/10 results, Stem Cell Research
Athersys (ATHX), Initiates Phase II Trial in Inflammatory Bowel Disease
March 14th, 2011
No comments
ATHX and Pfizer (PFE) collaborate on Stem Cell Therapy for Ulcerative Colitis (UC) Read more…
Categories: Initiation Phase II Trial, NASDAQ: ATHX, Stem Cell Research
Athersys (ATHX), Preclinical Data, MultiStem for Treating Stroke
February 21st, 2011
No comments
MultiStem therapy reduces inflammatory damage and improves functional recovery in preclinical models of Ischemic Stroke. Read more…
Athersys (ATHX), Research Note, Jason Kolbert, National Securities
February 1st, 2011
No comments
Athersys (ATHX) raised capital last week, gross proceeds of $13.1M, selling 4.3M shares with 0.3 warrants per share at a strike of $3.55. Read more…
Athersys (ATHX), Registered Direct Offering of $13.1M
January 28th, 2011
No comments
ATHX to sell 4,366,667 shares of its common stock and warrants Read more…
Athersys (ATHX) Retail Investor Conferences
January 24th, 2011
No comments
ATHX‘s 1/11/11, Retail Investor Conferences.com presentation is available for on-demand viewing. Read more…
MultiStem, a Spinal Cord Injury Stem Cell Therapy, Athersys (ATHX)
January 20th, 2011
No comments
Case Western Reserve and ATHX publish a study showing regenerative benefits of MultiStem’s therapy after Spinal Cord Injury reducing damage and promoting neuronal re-growth. Read more…
Completion of Patient Enrollment, PI Study of MultiStem, Athersys (ATHX)
January 7th, 2011
No comments
ATHX has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem(R) Read more…
Categories: NASDAQ: ATHX, PI Study of MultiStem, Stem Cell Technology
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.